Publication

A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: Application in a Dutch cancer clinic setting

van der Hout, A. H., van den Ouweland, AMW., van der Luijt, RB., Gille, HJP., Bodmer, D., Bruggenwirth, H., Mulder, IM., van der Vlies, P., Elfferich, P., Huisman, M. T., ten Berge, A. M., Kromosoeto, J., Jansen, RPM., van Zon, PHA., Vriesman, T., Arts, N., Lange, MBD., Oosterwijk, J. C., Meijers-Heijboer, H., Ausems, MGEM., Hoogerbrugge, N., Verhoef, S., Halley, DJJ., Vos, Y. J., Hogervorst, F., Ligtenberg, M. & Hofstra, R. M. W., Jul-2006, In : Human Mutation. 27, 7, p. 654-666 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • Annemarie H. van der Hout
  • AMW van den Ouweland
  • RB van der Luijt
  • HJP Gille
  • D Bodmer
  • H Bruggenwirth
  • IM Mulder
  • P van der Vlies
  • P Elfferich
  • Maarten T. Huisman
  • Annelies M. ten Berge
  • J Kromosoeto
  • RPM Jansen
  • PHA van Zon
  • T Vriesman
  • N Arts
  • MBD Lange
  • Jan C. Oosterwijk
  • H Meijers-Heijboer
  • MGEM Ausems
  • N Hoogerbrugge
  • S Verhoef
  • DJJ Halley
  • Yvonne J. Vos
  • F Hogervorst
  • M Ligtenberg
  • Robert M.W. Hofstra

Rapid and reliable identification of deleterious changes in the breast cancer genes BRCA1 and BRCA2 has become one of the major issues in most DNA services laboratories. To rapidly detect all possible changes within the coding and splice site determining sequences of the breast cancer genes, we established a semiautomated denaturing gradient get electrophoresis (DGGE) mutation scanning system. All exons of both genes are covered by the DGGE scan, comprising 120 amplicons. We use a semiautomated approach, amplifying all individual amplicons with the same PCR program, after which the amplicons are pooled. DGGE is performed using three slightly different gel conditions. Validation was performed using DNA samples with known sequence variants in 107 of the 120 amplicons; an variants were detected. This DGGE mutation scanning, in combination with a PCR test for two Dutch founder deletions in BRCA1 was then applied in 431 families in which 52 deleterious changes and 70 unclassified variants were found. Fifteen unclassified variants were not reported before. The system was easily adopted by five other laboratories, where in another 3,593 families both exons 11 were analyzed by the protein truncation test (PTT) and the remaining exons by DGGE. In total, a deleterious change (nonsense, frameshift, splice-site mutation, or large deletion) was found in 661 families (16.4%), 462 in BRCA1 (11.5%), 197 in BRCA2 (4.9%), and in two index cases a deleterious change in both BRCA1 and BRCA2 was identified. Eleven deleterious changes in BRCA1 and 36 in BRCA2 had not been reported before. In conclusion, this DGGE mutation screening method for BRCA1 and BRCA2 is proven to be highly sensitive and is easy to adopt, which makes screening of large numbers of patients feasible. The results of screening of BRCA1 and BRCA2 in more than 4,000 families present a valuable overview of mutations in the Dutch population. Hum Mutat 27(7), 654-666, 2006. (c) 2006 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)654-666
Number of pages13
JournalHuman Mutation
Volume27
Issue number7
Publication statusPublished - Jul-2006

    Keywords

  • hereditary breast, ovarian cancer, BRCA 1, BRCA2, mutation screening, DGGE, EARLY-ONSET BREAST, GRADIENT GEL-ELECTROPHORESIS, PROTEIN TRUNCATION TEST, MESSENGER-RNA DECAY, OVARIAN-CANCER, GERMLINE MUTATIONS, MISSENSE MUTATIONS, BRCA1/BRCA2 MUTATIONS, BREAST/OVARIAN CANCER, HEREDITARY BREAST

ID: 4444306